Immunopathogenesis of idiopathic nephrotic syndrome with relapse

Niaudet P (1993) Nephrotic syndrome in children. Curr Opin Pediatr 5:174–179 Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S (2002) Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 39:503–512 Mathieson PW (2007) Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 29:415–426 Kestila M, Lenkkeri U, Mannikko M et al (1998) Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582 Boute N, Gribouval O, Roselli S et al (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354 Hinkes B, Wiggins RC, Gbadegesin R et al (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397–1405 Kaplan JM, Kim SH, North KN et al (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256 Reiser J, Polu KR, Moller CC et al (2005) TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37:739–744 Lowik MM, Groenen PJ, Pronk I et al (2007) Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 72:1198–1203 Brown EJ, Schlondorff JS, Becker DJ et al (2010) Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 42:72–76 Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639 Guigonis V, Dallocchio A, Baudouin V et al (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279 Munyentwali H, Bouachi K, Audard V et al (2013) Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 83:511–516 Ravani P, Ponticelli A, Siciliano C et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025–1033 Zhang S, Audard V, Fan Q et al (2011) Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol 169:94–106 Yap HK, Cheung W, Murugasu B et al (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529–537 Lai KW, Wei CL, Tan LK et al (2007) Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 18:1476–1485 Van Den Berg JG, Aten J, Chand MA et al (2000) Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 11:413–422 Zhu P, Goh YY, Chin HF et al (2012) Angiopoietin-like 4: a decade of research. Bioscience reports 32:211–219 Koliwad SK, Gray NE, Wang JC. Angiopoietin-like 4 (Angptl4) (2012): A glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte.1:182–187. Koliwad SK, Kuo T, Shipp LE et al (2009) Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J Biol Chem 284:25593–25601 Koster A, Chao YB, Mosior M et al (2005) Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146:4943–4950 Clement LC, Avila-Casado C, Mace C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117–122 Reiser J, von Gersdorff G, Loos M et al (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113:1390–1397 Garin EH, Diaz LN, Mu W, Wasserfall C et al (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20: 260–266. Garin EH, MuW, Arthur JMet al (2010) Urinary CD80 is elevated in minimal change di sease but not in focal s egmental glomerulosclerosis. Kidney Int 78:296–302 Navarro-Munoz M, Ibernon M, Perez V et al (2011) Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients. Nephrol Dial Transplant 26:3914–3923 Yu CC, Fornoni A, Weins A et al (2013) Abatacept in B7-1-Positive Proteinuric Kidney Disease. N Engl J Med 2013 Sahali D, Pawlak A, Valanciute A et al (2002) A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 13:1238–1247 Grimbert P, Valanciute A, Audard V et al (2003) Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization. J Exp Med 198:797–807 Kamal M, Valanciute A, Dahan K et al (2009) C-mip interacts physically with RelA and inhibits nuclear factor kappa B activity. Mol Immunol 46:991–998 Zhang SY, Kamal M, Dahan K et al. (2010) c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal 3:ra39. Audard V, Zhang SY, Copie-Bergman C et al (2010) Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood 115:3756–3762 Cambier JF, Ronco P (2012) Onco-nephrology: glomerular diseases with cancer. Clin J Am Soc Nephrol 7:1701–1712 Sendeyo K, Audard V, Zhang SY et al (2013) Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. Kidney Int 83:414–425 Ory V, Fan Q, Hamdaoui N et al (2012) c-mip down-regulates NF-kappaB activity and promotes apoptosis in podocytes. Am J Pathol 180:2284–2292 Patrakka J, Tryggvason K (2007) Nephrin—a unique structural and signaling protein of the kidney filter. Trends Mol Med 13:396–403 New LA, Keyvani Chahi A, Jones N (2013) Direct regulation of nephrin tyrosine phosphorylation by Nck adaptor proteins. J Biol Chem 288:1500–1510 Huber TB, Hartleben B, Kim J et al (2003) Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 23:4917–4928 Quack I, Rump LC, Gerke P et al (2006) beta-Arrestin2 mediates nephrin endocytosis and impairs slit diaphragm integrity. Proc Natl Acad Sci U S A 103:14110–14115 Uchida K, Suzuki K, Iwamoto M et al (2008) Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int 73:926–932 Foster RR, Saleem MA, Mathieson PW et al (2005) Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 288:F48–F57 Schiffer M, Bitzer M, Roberts IS et al (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807–816 Schiffer M, Mundel P, Shaw AS et al (2004) A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 279:37004–37012 Shih NYLJ, Karpitskii V, Nguyen A et al (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312–315 Sakai N, Wada T, Furuichi K et al (2002) p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 17:998–1004 Stambe C, Nikolic-Paterson DJ, Hill PA et al (2004) p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 15:326–336 Koshikawa M, Mukoyama M, Mori K et al (2005) Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690–2701 Mima A, Kitada M, Geraldes P et al (2012) Glomerular VEGF resistance induced by PKCdelta/SHP-1 activation and contribution to diabetic nephropathy. FASEB J 26:2963–2974 Emoto Y, Manome Y, Meinhardt G et al (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148–6156 Kamal M, Pawlak BMAF et al (2010) C-mip interacts with the p85 subunit of PI3 kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase. FEBS Lett 584:500–506 Wang WJ, Kuo JC, Yao CC et al (2002) DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159:169–179 Gourlay CW, Carpp LN, Timpson P et al (2004) A role for the actin cytoskeleton in cell death and aging in yeast. J Cell Biol 164:803–809 Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136 Sison K, Eremina V, Baelde H et al (2010) Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21:1691–1701 Veron D, Reidy KJ, Bertuccio C et al (2010) Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 77:989–999 Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569–579 Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46:439–448 Echeverria V, Burgess S, Gamble-George J et al (2009) Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 162:1220–1231 Niaudet P, Gagnadoux MF, Broyer M (1998) Treatment of childhood steroid-resistant idiopathic nephrotic syndrome. Adv Nephrol Necker Hosp 28:43–61 Magnasco A, Ravani P, Edefonti A et al (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117–1124 Ramos EL (1991) Recurrent diseases in the renal allograft. J Am Soc Nephrol 2:109–121 Fairhead T, Knoll G (2010) Recurrent glomerular disease after kidney transplantation. Curr Opin Nephrol Hypertens 19:578–585 Canaud G, Martinez F, Noel LH et al (2010) Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. Transplant Rev (Orlando) 24:121–128 Cravedi P, Kopp JB, Remuzzi G (2013) Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 13:266–274 Hoyer JR, Vernier RL, Najarian JS et al (1972) Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 2:343–348 Kemper MJ, Wolf G, Muller-Wiefel DE (2001) Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 344:386–387 Ali AA, Wilson E, Moorhead JF et al (1994) Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 58:849–852 Rea R, Smith C, Sandhu K et al (2001) Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol Dial Transplant 16:416–417 Feld SMFP, Savin V, Nast CC (1998) Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 32:230–237 Ginsburg DSDP (1997) Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 48:282–287 Dantal J, Bigot E, Bogers W et al (1994) Effect of plasma protein adsorption on protein excretion in kidney- transplant recipients with recurrent nephrotic syndrome [see comments]. N Engl J Med 330:7–14 Dantal J, Godfrin Y, Koll R et al (1998) Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715 Savin VJ, Sharma R, Sharma M et al (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883 Boulton Jones JM, Tulloch I, Dore B et al (1983) Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 20:72–77 Yoshizawa N, Kusumi Y, Matsumoto K et al (1989) Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 51:370–376 Koyama A, Fujisaki M, Kobayashi M et al (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453–460 McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5:2115–2121 Wei C, El Hindi S, Li J, Fornoni A et al (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960 Eugen-Olsen J, Andersen O, Linneberg A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296–308 Bock ME, Price HE, Gallon L, Langman CB (2013) Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 8:1304–1311 Maas RJ, Wetzels JF, Deegens JK (2012) Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 81:1043–1044 Wei C, Trachtman H, Li J et al (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23:2051–2059 Franco Palacios CR, Lieske JC, Wadei HM et al (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96:394–399 Beaudreuil S, Zhang X, Kriaa F et al. (2013) Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis. Nephrol Dial Transplant. Nov 13 [Epub ahead of print]. Fornoni A, Sageshima J, Wei C et al (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46